ST Pharm Co.Ltd Total Liabilities
ST Pharm Co.Ltd total liabilities. Based on the latest financial reports, ST Pharm Co.Ltd (237690) has total liabilities worth ₩189.56 Billion KRW (≈ $128.46 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ST Pharm Co.Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ST Pharm Co.Ltd (2015–2025)
Total liabilities of ST Pharm Co.Ltd from 2015 to 2025. This chart illustrates how ST Pharm Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of ST Pharm Co.Ltd to see how much of total assets are deployed in long-term investments.
ST Pharm Co.Ltd Competitors by Total Liabilities
The table below lists competitors of ST Pharm Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bata India Limited
NSE:BATAINDIA
|
India | Rs21.83 Billion |
|
Energi Mega Persada Tbk
JK:ENRG
|
Indonesia | Rp926.48 Million |
|
Whirlpool China Co Ltd
SHG:600983
|
China | CN¥2.84 Billion |
|
Hefei Urban Construction Development Co Ltd
SHE:002208
|
China | CN¥22.82 Billion |
|
Hubei Jiuzhiyang Infrared System Co Ltd
SHE:300516
|
China | CN¥611.14 Million |
|
Aarti Pharmalabs Limited
NSE:AARTIPHARM
|
India | Rs-19.90 Billion |
|
Hangzhou Cogeneration Group Co Ltd
SHG:605011
|
China | CN¥1.24 Billion |
|
Jiangsu Shentong Valve Co Ltd
SHE:002438
|
China | CN¥2.42 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down ST Pharm Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ST Pharm Co.Ltd (237690) total assets.
Liquidity & Leverage Metrics
ST Pharm Co.Ltd Total Liabilities Ratios Explained
ST Pharm Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ST Pharm Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ST Pharm Co.Ltd (2015–2025)
The table below shows the annual total liabilities of ST Pharm Co.Ltd from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩189.56 Billion ≈ $128.46 Million |
-13.40% |
| 2024-12-31 | ₩218.88 Billion ≈ $148.33 Million |
-24.14% |
| 2023-12-31 | ₩288.53 Billion ≈ $195.53 Million |
+23.82% |
| 2022-12-31 | ₩233.02 Billion ≈ $157.91 Million |
+32.71% |
| 2021-12-31 | ₩175.59 Billion ≈ $119.00 Million |
+16.87% |
| 2020-12-31 | ₩150.24 Billion ≈ $101.82 Million |
+274.46% |
| 2019-12-31 | ₩40.12 Billion ≈ $27.19 Million |
+187.90% |
| 2018-12-31 | ₩13.94 Billion ≈ $9.44 Million |
-54.19% |
| 2017-12-31 | ₩30.42 Billion ≈ $20.62 Million |
-44.22% |
| 2016-12-31 | ₩54.53 Billion ≈ $36.96 Million |
-48.08% |
| 2015-12-31 | ₩105.04 Billion ≈ $71.18 Million |
-- |
About ST Pharm Co.Ltd
ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It… Read more